Pfizer in India is just as old as India is as a republic, having begun its operations in the country in 1950. Over the years, we have introduced many of Pfizer’s global breakthrough and innovative treatments in several major therapeutic areas, while also developing one of the country’s leading local brands portfolios to benefit millions of patients and consumers.
Pfizer operates in India through three legal entities: Pfizer Limited (listed on the Bombay Stock Exchange); Pfizer Products India Private Ltd (a 100% Pfizer Inc. subsidiary); and Pfizer Healthcare India Pvt. Ltd. (a 100% indirect subsidiary of Pfizer Inc focused on manufacturing and research). With over 5500 colleagues across these entities, covering commercial operations, global manufacturing, R&D, and other functions, we are committed to providing therapies to prevent, treat and cure some of the most important diseases that impact India and the world today.
Pfizer’s operations in India comprise three manufacturing plants, two R&D centers and six regional centers for commercial operations and global support functions.
Collectively, Pfizer in India is the fourth largest multinational pharmaceuticals company by revenue with a product portfolio of over 16 therapies, 3 manufacturing units with a combined capacity of 4.5 billion units; exports to over 50 countries and research in key areas such as Oncology, Immunology and Anti-infectives.
Pfizer Limited was listed on the Indian stock exchange in 1966. Today, the company has over one lakhshareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 16 therapeutic areas.
Its top brands include Prevenar 13, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.
Headquartered in Mumbai, Pfizer Products India Pvt Ltd (PPIPL) is a wholly owned subsidiary of Pfizer Inc. The company is engaged in importing, trading, marketing and distribution of pharmaceuticals products across key therapy areas such as Oncology, Rare Diseases and Anti-infectives.
Pfizer Healthcare India Private Limited (PHIPL), formerly Hospira Healthcare India Pvt. Ltd., was incorporated in India in 2009 as an Export Oriented Unit (EOU). PHIPL has global R&D centers and global manufacturing sites with FDI of over USD 1 billion and is aligned with the Indian Government’s ‘Make in India’ initiative.
PHIPL operates a state-of-the-art sterile injectables’ manufacturing site at Vishakhapatnam in Andhra Pradesh which is one of Pfizer’s largest such plants in the world. PHIPL manufactures medicines that are exported to over 30 countries and has been recognized by Ministry of Commerce & Industry with Make in India Excellence Awards for Highest Employment, Exports and NFEE in pharmaceuticals sector under EOU category (MEPZ) for the past 3 years. PHIPL’s world-class R&D center for small molecules in Chennai employs top scientific talent and is dedicated towards global research and development and technical support commercial manufacturing of parenteral products.